Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri scMRD Assay for AML. Learn More
X
Scientific presentation

Resolving tumor heterogeneity with single-cell co-detection of SNVs, CNVs, and immunophenotypes


Aaron Llanso
Description

Single-cell sequencing methods have enabled multi-modal characterization of tumor heterogeneity and yielded novel insights into tumor evolution, therapeutic response and resistance, and measurable residual disease (MRD). Aaron Llanson, DIrector of Market Development at Mission Bio, gives an overview of the Tapestri Platform and showcases the novel capability to co-detect SNVs, indels, CNVs, and immunophenotypes from the same cell with a single, high-throughput workflow. Single-cell multi-modal sequencing unlocks the ability to truly understand clonal architecture and resolve tumor heterogeneity.



VIEW


Scientific presentation
AML Single-cell Multi-omics MRD (scMRD) and the Horizon of Clinical Utility
Aaron Llanso
AMP 2022 (2022)
Scientific presentation
Molecular Analysis of Acute Myeloid Leukemia in Morphologic Remission
Sanam Loghavi, MD
AMP 2022 (2022)
Scientific presentation
Considerations, Strategies, and Advances in Early Drug Development to Mitigate Clinical Holds and Achieve Successful CGT Outcomes
Azadeh Golipour, PhD, AVROBIO
J. Kelly Ganjei, AmplifyBio
Scott R. Burger, MD, Advanced Cell and Gene Therapy
Matthew Cato
(2022)
Scientific presentation
Overview on Mission Bio’s Applications
Simone Formisano
Mission Bio EU Heme Symposium (2022)
REQUEST QUOTE